Data Updates in GI Cancers and HCC from ESMO 2024 - Episode 1

5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

,

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.

Now Viewing
EP. 1: 5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC
EP. 2: The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC
EP. 3: Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial
EP. 4: Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
EP. 5: Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
EP. 6: Building Upon Approved Combination Regimens in Unresectable HCC
EP. 7: Ongoing Research in GI Cancers

Related Content:

Karmanos Cancer InstituteGastrointestinal CancerHepatocellular Carcinoma
Combination Regimens Make Their Mark in Frontline HCC
Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab